Industries > Pharma > Global Oncology Pricing, Reimbursement & Market Access 2019-2029

Global Oncology Pricing, Reimbursement & Market Access 2019-2029

US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China

PUBLISHED: 10 September 2019
PAGES: 292
PRODUCT CODE: PHA0522
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0522 Categories: , Tags: , ,

The global oncology pricing, reimbursement and market access report provides analysis and evaluation of the current and prospective economic burden of cancer treatment in the US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China. This report also outlines historical and current healthcare status for the selected markets with respect to expenditures along with the healthcare system that governs medical access.

In this report, we provide comprehensive view on some of the trends for top-seller oncology drugs including payer’s perspective on cancer outcomes, impact of these high cost drugs, standard guidelines preferred for different cancers, availability and costs of oncology therapeutics and complexity in cancer treatments as well as epidemiology of different cancer types.

How this report will benefit you
In this brand new 292-page report you will receive 98 charts– all unavailable elsewhere.

The 292-page report provides clear detailed insight into the global oncology pricing, reimbursement & market access. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Key questions answered by this report:
• Factors Affecting Pricing and Reimbursement Decision
• Pricing Negotiations and Discounts
• Reimbursement Policies
• Role of HEOR and Economic Value Planning
• Drug Patent Expiry and Effects on Pricing
• Cost-Effectiveness Analysis

• This report discusses healthcare system, pricing & reimbursement process, HTA, oncology cost of treatment, payer insights, healthcare expenditure, health coverage, key formularies, role of pharmacists, regulatory & approval process for these countries:
• United States
• Canada
• Germany
• France
• UK
• Italy
• Spain
• Japan
• Australia
• Brazil
• Russia
• India
• China

• Discussion on parallel import and its impact in the US and Europe.

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Oncology Pricing, Reimbursement and Market Access. You find data, trends and predictions.

Buy our report today Global Oncology Pricing, Reimbursement & Market Access 2019-2029: US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Global Oncology Pricing, Reimbursement & Market Access 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Global Oncology Pricing, Reimbursement & Market Access 2019-2029


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories

Category